The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Mesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to Intracranial Glioma
Abstract
Gene therapy represents a promising treatment alternative for patients with malignant gliomas. Nevertheless, in the setting of these highly infiltrative tumors, transgene delivery remains a challenge. Indeed, viral vehicles tested in clinical trials often target only those tumor cells that are adjacent to the injection site. In this study, we examined the feasibility of using human mesenchymal stem cells (hMSC) to deliver a replication-competent oncolytic adenovirus (CRAd) in a model of intracranial malignant glioma. To do so, CRAds with a chimeric 5/3 fiber or RGD backbone with or without CXCR4 promoter driving E1A were examined with respect to replication and toxicity in hMSC, human astrocytes, and the human glioma cell line U87MG by quantitative polymerase chain reaction and membrane integrity assay. CRAd delivery by virus-loaded hMSC was then evaluated in vitro and in an in vivo model of mice bearing intracranial U87MG xenografts. Our results show that hMSC are effectively infected by CRAds that use the CXCR4 promoter. CRAd-CXCR4-RGD had the highest replication, followed by CRAd-CXCR4–5/3, in hMSC, with comparable levels of toxicity. In U87MG tumor cells, CRAd-CXCR4–5/3 showed the highest replication and toxicity. Virus-loaded hMSC effectively migrated in vitro and released CRAds that infected U87MG glioma cells. When injected away from the tumor site in vivo, hMSC migrated to the tumor and delivered 46-fold more viral copies than injection of CRAd-CXCR4–5/3 alone. Taken together, these results indicate that hMSC migrate and deliver CRAd to distant glioma cells. This delivery strategy should be explored further, as it could improve the outcome of oncolytic virotherapy for glioma. Disclosure of potential conflicts of interest is found at the end of this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone Marrow Stromal Stem Cells: Nature, Biology, and Potential Applications
Bianco, P., Riminucci, M., Gronthos, S., & Robey, P. G. (2001) · STEM CELLS · doi:10.1634/stemcells.19-3-180 · Cited by 1,939
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1874 · Cited by 1,035
Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers
Friedenstein, A. J., Chailakhyan, R. K., & Gerasimov, U. V. (1987) · Cell Proliferation · doi:10.1111/j.1365-2184.1987.tb01309.x · Cited by 983
Ponte, A. L., Marais, E., Gallay, N., Langonné, A., Delorme, B., Hérault, O., Charbord, P., & Domenech, J. (2007) · STEM CELLS · doi:10.1634/stemcells.2007-0054 · Cited by 947
Lee, R. H., Kim, B., Choi, I., Kim, H., Choi, H. S., Suh, K., Bae, Y. C., & Jung, J. S. (2004) · Cellular Physiology and Biochemistry · doi:10.1159/000080341 · Cited by 931
Honczarenko, M., Le, Y., Swierkowski, M., Ghiran, I., Glodek, A. M., & Silberstein, L. E. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0319 · Cited by 722
Son, B., Marquez‐Curtis, L. A., Kucia, M., Wysoczynski, M., Turner, A. R., Ratajczak, J., Ratajczak, M. Z., & Janowska‐Wieczorek, A. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0271 · Cited by 641
Sordi, V., Malosio, M. L., Marchesi, F., Mercalli, A., Melzi, R., Giordano, T., Belmonte, N., Ferrari, G., Leone, B. E., Bertuzzi, F., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3507 · Cited by 602
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma.
Ehtesham, M., Kabos, P., Kabosova, A., Neuman, T., Black, K. L., & Yu, J. S. (2002) · PubMed · Cited by 308
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Komarova, S., Kawakami, Y., Stoff-Khalili, M. A., Curiel, D. T., & Pereboeva, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0334 · Cited by 302
Sandmair, A.-M., Loimas, S., Puranen, P., Immonen, A., Kossila, M., Puranen, M., Hurskainen, H., Tyynelä, K., Turunen, M., Vanninen, R., et al. (2000) · Human Gene Therapy · doi:10.1089/104303400750035726 · Cited by 300
Louis, D. N., Holland, E. C., & Cairncross, J. G. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61750-6 · Cited by 298
A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.
Suzuki, K., Fueyo-Margareto, J., Krasnykh, V. N., Reynolds, P. N., Curiel, D. T., & Alemany, R. (2001) · PubMed · Cited by 286
Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives
Hirschfeld, S., Ho, P. T. C., Smith, M., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.138 · Cited by 229
Stoff-Khalili, M. A., Rivera, A. A., Mathis, J. M., Banerjee, N. S., Moon, A. S., Hess, A., Rocconi, R. P., Numnum, T. M., Everts, M., Chow, L. T., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9449-8 · Cited by 205
Self-citationOptimized Real-Time Quantitative PCR Measurement of Male Fetal DNA in Maternal Plasma
Zimmermann, B., El-Sheikhah, A., Nicolaides, K., Holzgreve, W., & Hahn, S. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.051235 · Cited by 165
Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors
Short, J. J., Pereboev, A. V., Kawakami, Y., Vasu, C., Holterman, M. J., & Curiel, D. T. (2004) · Virology · doi:10.1016/j.virol.2004.02.016 · Cited by 164
Ehtesham, M., Yuan, X., Kabos, P., Chung, N. H. C., Liu, G., Akasaki, Y., Black, K. L., & Yu, J. S. (2004) · Neoplasia · doi:10.1593/neo.03427 · Cited by 160
Conget, P. A., & Minguell, J. J. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00134-x · Cited by 148
Epidemiologic Study of Primary Intracranial Neoplasms
Annegers, J. F., Schoenberg, B. S., Okazaki, H., & Kurland, L. T. (1981) · Archives of Neurology · doi:10.1001/archneur.1981.00510040043006 · Cited by 137
Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells
Ziu, M., Schmidt, N. O., Cargioli, T. G., Aboody, K. S., Black, P. M., & Carroll, R. S. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9121-5 · Cited by 93
Lichtenstein, D. L., & Wold, W. S. M. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700765 · Cited by 77
CD46 Represents a Target for Adenoviral Gene Therapy of Malignant Glioma
Ulasov, I. V., Tyler, M. A., Zheng, S., Han, Y., & Lesniak, M. S. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.556 · Cited by 58
Self-citationKnaän‐Shanzer, S., van de Watering, M. J. M., van der Velde, I., Gonçalves, M. A. F. V., Valerio, D., & de Vries, A. A. F. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0016 · Cited by 57
Serfözö, P. D., Schlarman, M. S., Pierret, C., et al. (2006) · Cancer Cell International · doi:10.1186/1475-2867-6-1 · Cited by 54
Zhu, Z. B., Makhija, S. K., Lu, B., Wang, M., Rivera, A., Kim‐Park, S., Ulasov, I. V., Zhou, F., Alvarez, R. D., Siegal, G., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.1.237 · Cited by 48
Self-citationMajem, M., Cascalló, M., Bayó-Puxan, N., Mesı́a, R., Germà, J. R., & Alemany, R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700940 · Cited by 38
Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus
Tyler, M. A., Ulasov, I. V., Borovjagin, A. V., Sonabend, A. M., Khramtsov, A., Han, Y., Dent, P., Fisher, P. B., Curiel, D. T., & Lesniak, M. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0187 · Cited by 37
Self-citationTargeting lung cancer using an infectivity enhanced CXCR4-CRAd
Zhu, Z. B., Rivera, Á. A., Makhija, S. K., Lu, B., Wang, M., Izumi, M., Cerfolio, R. J., Stoff‐Khalili, M. A., Zhou, F., Takayama, K., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.10.012 · Cited by 12
Cited by
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Oxygen in Stem Cell Biology: A Critical Component of the Stem Cell Niche
Mohyeldin, A., Garzón-Muvdi, T., & Quiñones-Hinojosa, A. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.007 · Cited by 1,535
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Batrakova, E. V., Gendelman, H. E., & Kabanov, A. V. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.559457 · Cited by 323
Mesenchymal stem cells engineered for cancer therapy
Shah, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.010 · Cited by 322
Metadata
- Authors
- Sonabend, A. M., Ulasov, I. V., Tyler, M. A., Rivera, A. A., Mathis, J. M., & Lesniak, M. S.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01-10
- Volume
- 26
- Issue
- 3
- Pages
- 831-841
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2022922272
- Cited by
- 254
- References
- 32
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.